Lung Cancer Articles | Page 2

Biomarkers in NSCLC Poised to Expand in Coming Years
Ravi Salgia, MD, PhD, discusses the evolution and current state of biomarker testing in the field of NSCLC.
Treatment Paradigm Evolving in Early-Stage Lung Cancer
Dan J. Raz, MD, discusses the ongoing ALCHEMIST trial and some novel techniques, such as tissue slice culture, that are propelling the field of lung cancer forward
Plinabulin Combo With Docetaxel Aimed at Delivering a
Plinabulin, an antineoplastic agent that activates an immune response, is being investigated as a treatment option for patients with advanced or metastatic non–small cell lung cancer who have progressed after standard-of-care therapy.
Loretta Erhunmwunsee, MD, discusses the racial and socioeconomic disparities in lung cancer trials
Reckamp Recounts Recent Lung Cancer Advances
Karen Reckamp, MD, discusses positive phase III data, recent regulatory approvals, and what research the new year is likely to bring to the field of non-small cell lung cancer (NSCLC).
Liquid Biopsies a Quicker Alternative to Standard Approaches in NSCLC
Jared Weiss, MD, discusses utilizing liquid biopsies for patients with lung cancer, the pros and cons of the approach, and when it might be appropriate to rebiopsy patients.
Biomarker Testing Continues to Develop in NSCLC
Kathryn F. Mileham, MD, discusses the development of biomarker testing for patients with mutated non-small cell lung cancer.
Various Immunotherapy Combinations Continue to Be Explored in NSCLC
Daniel E. Haggstrom, MD, discusses the developing area of immunotherapy combinations for patients with non-small cell lung cancer.
Expert Sheds Light on Lesser-Known Mutations in NSCLC
Raghava R. Induru, MD, discusses lesser-known mutations in non-small cell lung cancer, such as TRK and BRAF.
Immunotherapy/RT Combos Could Be Next Wave of Novel Treatment in Lung Cancers
Sagus Sampath, MD, discusses ongoing studies exploring checkpoint inhibitors with radiation therapy and the promise of integrating these 2 treatments in the field of non-small cell lung cancer.
Publication Bottom Border
Border Publication